Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
dmceng,
End of March I think
pma_56
You raise an interesting point,
I had always thought that DNAG would be bought out by big pharma because of the potential profits involved and DNAG's lack of funding.
Now we are selling at a few million for a company with billions in poential product sales (many products well on their way through R&D).
So why don't we see an offer a few million above nanobac with this company at bargin basement prices?
pma_56
What have you got to lose at this point. LOL
http://www.gatesfoundation.org/AboutUs/WorkingWithUs/ContactUs/
If you want to apply for funding, please go to our Grant Seekers page; to comment on our Web site, please send an email to our Web team.
Bill & Melinda Gates Foundation
PO Box 23350
Seattle, WA 98102
Phone: (206) 709-3100 (Reception)
(206) 709-3140 (Grant Inquiries)
Email: info@gatesfoundation.org
East Coast Office
PO Box 6176
Ben Franklin Station
Washington, D.C. 20044
Media Inquiries (Press Only)
PO Box 23350
Seattle, WA 98102
Phone: (206) 709-3400
Fax: (206) 709-3252
Email: media@gatesfoundation.org
Note: If you are a member of the news media, please use the phone number or email address above to leave a detailed message. Include your name, press affiliation, phone number, questions, and deadline. We check messages every hour between 6 a.m. and 5 p.m. Pacific Time.
If you have an urgent deadline and require immediate assistance, you can page us at (206) 236-4774. Our pager system is for urgent, imminent-deadline requests only.
stockhlder101,
"I took my lumps here!! ... , but I have moved on to much greener pastures..."
did you really? LOL
stockhlder101 Thank you,
Best post of the day!
sam,
thank you for continuing to post useful information.
All the speculation is just that. I will rant or cheer when the time comes.
jever0,
where did you find the info in post 76596?
You listed a link to nanobac at the bottom but I don't see it on their site.
It would be nice to know how the seminar affected the papers of those who were there.
PL1,
Right, I was refering to the post by jever that says,"Half-a-dozen papers in the Journal resulted from a symposium" forth paragraph.
I don't know if it is about Nanobac or not,
From Jever0
2/10/2008 11:16:17 PM
New Evidence on Infection as Chronic Disease Trigger Published, Debated by World-Class Scientists
Nanobac Pharmaceuticals Inc. announces new evidence that may help solve one of the great puzzles of 21st century medicine was published in a special section of the Journal of Investigative Medicine. It features leading scientists in the field brought together by The American Federation for Medical Research and the American Physiological Society.
Is chronic disease triggered by an infection? New evidence comes from scientists at NASA, Mayo Clinic, and Nanobac Pharmaceuticals who pioneered investigations into infectious calcifying particles.
A condition known as calcification occurs in most diseases on the leading cause of death list and in illnesses such as kidney, gallbladder and prostate stones. Calcification is also linked to chronic inflammation in atherosclerosis and end-stage renal disease, but it is unclear how this occurs.
Half-a-dozen papers in the Journal resulted from a symposium that assembled, for the first time in medical history, experts from biology, medicine and geology to debate these possible causes of calcification: chemical crystallization; cell-mediated crystallization; and potentially infectious calcifying nanoparticles (CNPs) that generate calcification.
One conclusion by symposium organizers: Although infection is just one of three potential causes of calcification, it deserves focus as a chronic disease trigger, based on new evidence presented. "Increasingly, micro-organisms are being identified as an unexpected cause of disease..." writes symposium co-organizer and Mayo Clinic scientist Dr. Virginia Miller.
The symposium considered works by Dr. Neva Ciftcioglu and Dr. Olavi Kajander, lead scientists with Nanobac Pharmaceuticals, as well as two other works by Mayo researchers, which provide evidence that calcifying nanoparticles might be infectious and spark calcification in disease.
"Although Dr. Miller says the idea of infectious nanoparticles is still controversial, she concludes that, "Nanoparticles might serve as an inflammatory stimulus that initiates cell transdifferentiation, stimulate the formation of matrix vesicles, or simply form a nidus for subsequent inorganic calcium accumulation."
Participants in the symposium included scientists from such world-class institutions as UCLA and various institutes in Europe.
Scientists from Nanobac Pharmaceuticals are the leading investigators on the issue of infection as a possible cause of calcification, and have published the most papers on this topic."
jever0,
nice find!
PL1, I've been looking throught the Journal of Investigative Medicine. "For Half-a-dozen papers in the Journal resulted from a symposium that assembled," But no luck,can you help?
Thanks,
Smart people, a question...
Will DNAG add NANOBAC's tests to protectin so they can better test at risk diabetic patients. Is that the implication here? Is that the main connection between DNAG and NANOBAC?
"The Protectin(TM) test will be used to identify diabetics at risk of developing vascular complications," said Dr. Gomez, Chairman of DNAP. "Protectin(TM) is anticipated to become a new tool in the complex understanding of Diabetes and could potentially replace HbA1c, the current test used to evaluate glucose control. Combined with Nanobac's diagnostic portfolio, Protectin(TM) is expected to dramatically increase the physician's ability to diagnose patients at significant cardiovascular risk," concluded Dr. Gomez.
PL1, a little help?
chigga posted this (thanks chigga)and the statements sound like they are suggesting that calcification is the CAUSE of these diseases.
If so are they suggesting that if they remove the calcification that they can prevent or cure the diseases? Or are they suggesting that it is one part of the disease process?
Nanobacteria has been shown by multiple scientific researchers to be the cause of the pathological (disease-causing) calcification found in Atherosclerotic Plaque, Coronary Artery Plaque, Heart Disease, Kidney Stones, Polycystic Kidney Disease (PKD), Cataracts, Scleroderma, Psoriasis, Eczema, Lichen planus, Liver Cysts, Breast Calcification, Prostate Calcification, Dental Plaque and Periodontal Disease, Rheumatoid Arthritis, Osteoarthritis, Fibromyalgia, Spurs and have been implicated to be involved in certain cancers, blood disorders, and myelodegenerative disorders such as Multiple Sclerosis, Lou Gehrig's and Alzheimer’s Disease.
Ann,
My optimism about DNAG has slowly dwindled over the past 7 years until I had none.
With this acquisition my hope is renewed. I have no Idea what the acquisition terms will be but like the longterm prospects NANOBAC offers (financing for DNAG projects). JMO
Unless news comes out that disuades me I plan to hold onto my DNAG/NANOBAC shares to see what the future brings. JMO
Thanks,
Guess I'll take a "quiet period" myself until news.
alterboy4, Iwant2be,
Agree completely,
I had expected DNAG to post the offer details by now. Does anyone know if there is a SEC time limit on disclosure for this?
I have always been impressed with DNAG science.
But businessmen, they are not. I think they actually believed they could bring a new product to market every 6 months as they once claimed and that the DNAG name on a racecar was advertising.
Nanobac is the reverse. IMO I feel that he knows nothing about the science. He is in it purely for the money. He invests in a wide variety of projects and focuses on the financial side. In short a business man and financier.
Will DNAG and Nanobac be a good match?
Don't ask me,I bought most of my DNAG shares before the split. DOH
ANN441,
Thank you for all the new information,
"DNAG's primary objective has been, and Nanobac's primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters."
SO this is the NEW PRIMARY OBJECTIVE of Nanobac and the reason they bought DNAG. First thing that has made sense to me about the acquisition.
Yea,
The science is fun and exciting. Tremendous possibilities. NANOBAC too.
Some great people on this board also, PL1, Chrisbaskett, Johnnyfiber etc.
You are right in a sense, but our thinking was that DNAG had good products and technology that much larger companies would be interested in for one reason or another but even though DANG lacked the fundamental business savvy to market or complete their products on their own, a larger company could not be found so easily. So they sold for squat.
Still you are right in a sense, I think there chances have much improved with NANOBAC. The owner seems MUCH better at finding good financing. Funding was the one thing DNAG suced at.
Good luck to us all
Stockboy,
"HAHA you'll be lucky to see .005!"
"they did nothing but go down LOL"
"nnbc is a penny stock lol"
"LOL The long's are getting suh suh S C R E W E D!"
Few people ever realize the joy, the happiness, the laughter to be had in watching the suffering of others. Congrats! Glad someone here is enjoying themselves.
Johnnyfiber,
Regards your last 2 posts. ....67 ....77
Are these posted to the right board? How do they pertain to DNAG, NANOBAC, nano technolgy or genomics in general.
alterboy4,
If NANOBEC puts out a press release announcing major funding before DNAG puts out their PR we could see a nice jump in SP.
Just speculating.
Another thought, we do not seem to be the only acquisition NANOBAC is making at this time (see johnyfibers posts). They are going out on a vary thin limb if they don't have funding. This makes me suspect that they are confident of their funding.
again just speculating
Of course DNAG went out on that limb without funding but they were (can't use words like that here)
alterboy4
johnnyfiber posted a link to this info post 76026
it is dated 27.09.2007 15:19
johnnyfiber,
Thanks for the informitive posts.
Would you mind giving your opinion on the acquisition of DNAG?
("Nanobac" or "the Company") is pleased to announce that its Board of Directors has approved an interim financing package that will allow the Company to meet its scientific and business initiatives through the end of the year. This financing is a debt instrument which is being secured by management and should have minimal to no dilution to shareholders."
"approved an interim financing package"
"should have minimal to no dilution to shareholders."
They seem much better at getting financing on better terms than DNAG.
Would have loved to hear DNAG make a statements like those
Nanobac (News) Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce that its Board of Directors has approved an interim financing package that will allow the Company to meet its scientific and business initiatives through the end of the year. This financing is a debt instrument which is being secured by management and should have minimal to no dilution to shareholders.
The Company's Board of Directors also approved a stock buy back program which will allow for the Company and Management to buy back up to 20% of the outstanding float. This action was taken as a step to show management belief that the Company is significantly undervalued and the Board of Director's commitment to the Company's future success. This buy back will take place over the course of the next year.
“The significant advancements in our research and development program as well as our sales and marketing initiatives, makes these strategic moves the next logical step in the company's progression,“ commented Alex H. Edwards III, Director Nanobac Pharmaceuticals. “We are now actively interviewing investment banking firms to start the process of a significant funding event in late 2007 early 2008,“ Edwards concluded.
I found this post n the Yahoo NANOBAC message board.
The co mentioned in a late 2007 news
release that major financing would be
announced early 2008, but did not elaborate.
If i find the news release will post it,
relying on my memory here.
We are about due for another shareholder update!
Nanotwin are you Nanopatent? Thought so...
Under topic-- DNAG Shareholder question posted bycarol43015
If true, could explain where the money is comming from. I am trying to varify the statement now.
chiggah,
It will be interesting to see where all this leads, it looks like they may be a good match for DNAG. Time will tell.
thanks for the information, it was extreamly useful.
ciggah,
Sorry to here about your operation.
Please enlighten me. What have you found.
Speculation,
No one knows what will happen with the deal but the negitive spectulation hurts the SP. It will not go as high on spectulation before the announcement.
All the loyal longs who want to sell on spectulation (hopefully a nice runup) before news are being hurt by your posts.
After all this time the loyal longs deserve the best they can get.
To just keep your opinions until the announcment costs you nothing. If you sell beforehand, the negitive comments could cost you alot.
Anyway, I believe in free speech, not trying to tell you what you should post (or think), it's all just food for thought. ALL JMHO.
Personally I intend to hold.
Whatever you do, best of luck to all the longs
Superbowl Sunday,
ENJOY!
I'm out a here, (investorshub not DNAG)posted more times in the last two days than in the last 7 years combined.
Hoping for the best with the acquistion
Good luck everyone
FYI Fridays press release.....
Press Release Source: Nanobac Pharmaceuticals Inc.
Nanobac Pharmaceuticals Inc. Signs LOI for the Acquisition of DNAPrint Genomics
Friday February 1, 11:55 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company”) is pleased to announce a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc. (OTCBB:DNAG - News) (“DNAPrint” or DNAP). With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development. Nanobac adds advanced drug and diagnostics development programs, key patents and patent applications, and a proprietary product modeling platform to its existing initiatives, and expands its focus into multiple disease sites for both Diagnostics and Therapeutics.
The combined company would have annualized revenue of approximately $5,000,000, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University.
DNAPrint Genomics has developed, patented and published various technologies for an improved, 21st century model of clinical product development - aimed at maximizing effectiveness, minimizing unintended effects, reducing costs and shifting the risk to reward ratio during clinical product development. These tools include extensively validated and published genome assays for individualized assessments of genetic ancestry on multiple levels (consumer products segment), tools for the inference of physical characteristics for the forensics market, tools for the inference of patient proclivities to respond to treatments (pharmacogenomics) and meta-analytical systems for computationally modeling the biology of clinical products for a more intelligent approach to drug and diagnostic development. DNAG's primary objective has been, and Nanobac's primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters. DNAG's flagship product, PT-401, is expected to result in more effective treatment of anemia, and its Protectin(TM) (CD-59) diagnostic test is expected to allow patients and their physicians to more effectively manage the risks and treatment decisions for diabetes. DNAG supports its clinical programs, in part, through the sale of consumer genetics tests genotyping services on a contractual basis.
“Dr Hector Gomez has been on the Company’s advisory board giving Nanobac the benefit of evaluating DNAG’s technologies and portfolio of products,” said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals. “Combining our diagnostic portfolios, specifically DNAP’s Protectin™ and Nanobac’s NB2 has the potential to play a significant role in the early diagnosis of vascular disease and could potentially help in identifying early signs and progression of cardiovascular disease,” Dr. Maniscalco concluded.
"The Protectin(TM) test will be used to identify diabetics at risk of developing vascular complications," said Dr. Gomez, Chairman of DNAP. "Protectin(TM) is anticipated to become a new tool in the complex understanding of Diabetes and could potentially replace HbA1c, the current test used to evaluate glucose control. Combined with Nanobac's diagnostic portfolio, Protectin(TM) is expected to dramatically increase the physician's ability to diagnose patients at significant cardiovascular risk," concluded Dr. Gomez.
According to Global Industry Analysts, the international global diabetes diagnostic supplies market is expected to grow to US$15.4 billion by 2010. This indicates significant potential for the Protectin™ test. Additionally, cardiovascular diagnostics will see a high rate of growth also, increasing from $11.9 billion in 2007 to $21.4 billion by the end of 2012. The cardiovascular diagnostics market represents one of the largest sectors within the diagnostics industry, chiefly due to the high prevalence rate of and high mortality rate from cardiovascular disease.
DNAG’s flagship PT-401 therapeutic, in pre-clinical stages, is a genetically engineered erythropoietin dimmer (double form), which elicits a heartier, longer lasting increase in hematocrit for anemic patients. The singlet form of erythropoietin was introduced by Amgen Corporation in 1989, and enjoys a $2B in annual sales. A successfully approved PT-401 alternative is expected to allow physicians to treat patients with less drug and at less frequent intervals, at significant savings, while at the same time, increasing the consistency of therapeutic response.
Nanobac Pharmaceuticals is the leader in research and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac Pharmaceuticals markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
Contact:
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348
--------------------------------------------------------------------------------
Source: Nanobac Pharmaceuticals Inc.
nanopatent,
all we have to go on at the moment is from the news release (plus a hundred "possibilities" in my own mind)
from the release
"“Combining our diagnostic portfolios, specifically DNAP’s Protectin™ and Nanobac’s NB2 has the potential to play a significant role in the early diagnosis of vascular disease and could potentially help in identifying early signs and progression of cardiovascular disease,” Dr. Maniscalco concluded.
"The Protectin(TM) test will be used to identify diabetics at risk of developing vascular complications," said Dr. Gomez, Chairman of DNAP. "Protectin(TM) is anticipated to become a new tool in the complex understanding of Diabetes and could potentially replace HbA1c, the current test used to evaluate glucose control. Combined with Nanobac's diagnostic portfolio, Protectin(TM) is expected to dramatically increase the physician's ability to diagnose patients at significant cardiovascular risk," concluded Dr. Gomez.
According to Global Industry Analysts, the international global diabetes diagnostic supplies market is expected to grow to US$15.4 billion by 2010. This indicates significant potential for the Protectin™ test. Additionally, cardiovascular diagnostics will see a high rate of growth also, increasing from $11.9 billion in 2007 to $21.4 billion by the end of 2012. The cardiovascular diagnostics market represents one of the largest sectors within the diagnostics industry, chiefly due to the high prevalence rate of and high mortality rate from cardiovascular disease.
DNAG’s flagship PT-401 therapeutic, in pre-clinical stages, is a genetically engineered erythropoietin dimmer (double form), which elicits a heartier, longer lasting increase in hematocrit for anemic patients. The singlet form of erythropoietin was introduced by Amgen Corporation in 1989, and enjoys a $2B in annual sales. A successfully approved PT-401 alternative is expected to allow physicians to treat patients with less drug and at less frequent intervals, at significant savings, while at the same time, increasing the consistency of therapeutic response."
heavy d,
" I think that 5 million in annual sales is a joke"
if you are talking about "potential income". DNAG itself has billions in annual "potential sales" just with it's current "in the pipeline" drugs (that it can't afford to go forward with).
The news release suggests this DNAG's efforts to date will effect the price.
from the news release...
"Dr Hector Gomez has been on the Company’s advisory board giving Nanobac the benefit of evaluating DNAG’s technologies and portfolio of products"
How much Nanobac will pay for our "portfolio of products" remains to be seen.
FSAIL52,
I posted that same question eairler, I suspect Chrisbaskett is correct.
Chrisbaskett, I to am a loooooong term holder of DNAG. What a long strange trip it's been.
Chrisbaskett,
"I'd be very surprised if it is over .02 IMO more like .01"
Although my GUESS would be much higher....too many unknowns.
It does look like we are dealing with a great Co. with huge potential. (like DNAG)
They seem well connected with Pharma and on good financial ground. (unlike DNAG).
Good luck to all
TheBigLab,
I'm suprised at the estimates of .02 It's anybody's guess but I would think it would be MUCH higher.
Anyone care to estimate when we will hear the price?
pennypusher1,
looks like it
from todays news release
"("Nanobac" or "the Company”) is pleased to announce a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc. (OTCBB:DNAG - News) (“DNAPrint” or DNAP). With the acquisition, which is subject to DNAPrint Genomics shareholder approval,
jkids210
Don't have the answer to that. But yes shares are a possibility. We will have to wait and see.
Anyone have any idea if the shareholders can stop this deal with the vote or are we short on % of shares held. That is, if we don't like the deal.